Menu
Search
|

Menu

Close
X

Array Biopharma Inc ARRY.OQ (NASDAQ Stock Exchange Global Market)

16.38 USD
+0.67 (+4.26%)
As of Nov 16
chart
Previous Close 15.71
Open 15.54
Volume 1,069,773
3m Avg Volume 693,464
Today’s High 16.67
Today’s Low 15.44
52 Week High 20.20
52 Week Low 10.37
Shares Outstanding (mil) 213.07
Market Capitalization (mil) 3,134.29
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
57
FY18
174
FY17
151
FY16
138
FY15
52
EPS (USD)
FY19
-0.117
FY18
-0.746
FY17
-0.718
FY16
-0.649
FY15
-0.013
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
15.60
20.58
Price to Book (MRQ)
vs sector
14.30
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
59.84
13.84
LT Debt to Equity (MRQ)
vs sector
59.84
9.93
Return on Investment (TTM)
vs sector
-33.09
13.58
Return on Equity (TTM)
vs sector
-60.20
15.11

EXECUTIVE LEADERSHIP

Carrie Cox
Independent Chairman of the Board, Since 2018
Salary: --
Bonus: --
Ron Squarer
Chief Executive Officer, Director, Since 2012
Salary: $615,760.00
Bonus: $473,582.00
Jason Haddock
Chief Financial Officer, Since 2016
Salary: $377,770.00
Bonus: $193,375.00
Andrew Robbins
Chief Operating Officer, Since 2015
Salary: $446,456.00
Bonus: $257,528.00
Curtis Oltmans
Executive Vice President, General Counsel, Secretary, Since 2017
Salary: $351,538.00
Bonus: $154,604.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3200 Walnut St
BOULDER   CO   80301-2514

Phone: +1303.3816600

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

SPONSORED STORIES